Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
FDA approves new efficacy supplement for Eli Lilly's VerzenioSep 18Regulatory decisionabemaciclibEli Lilly
Lilly's orforglipron posts Phase 3 diabetes results; six new trials registeredSep 18Weekly roundup, 7 itemsEli Lillyorforglipron
AstraZeneca's SERENA-4 trial misses main goal for Etcamah in first-line breast cancerSep 14Clinical readoutAstraZenecacamizestrant
FDA approves AstraZeneca's Etcamah for HR-positive breast cancerSep 8Regulatory decisionAstraZenecacamizestrant
FDA drug application records confirm Etcamah approval details, dosage formSep 4Regulatory decisionAstraZenecacamizestrant
Lilly registers Phase 3 depression trial; posts results for two psoriasis and oncology studiesAug 20Weekly roundup, 5 itemsabemaciclibbrenipatide
LeonaBio reports Q2 2026 results, enrollment nears completion for ELAINE-3 trialAug 14Clinical readoutLeonaBio
AstraZeneca's Etcamah wins EU approval for 1st-line ER+ breast cancerJul 23Regulatory decisionAstraZenecacamizestrant
AstraZeneca registers Phase III bladder cancer trial; joins Natera-led breast cancer studyJul 23Weekly roundup, 5 itemsAstraZenecaAZD6489
FDA approves efficacy-related supplement for Eli Lilly's VerzenioJul 13Regulatory decisionabemaciclibEli Lilly
Lilly posts ACHIEVE-J results; Olumiant, Strattera labels updatedJul 2Weekly roundup, 5 itemsabemaciclibbaricitinib
Sign inSign in